Search

Your search keyword '"Hernandez Á"' showing total 742 results

Search Constraints

Start Over You searched for: Author "Hernandez Á" Remove constraint Author: "Hernandez Á" Journal blood Remove constraint Journal: blood
742 results on '"Hernandez Á"'

Search Results

1. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

2. NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression

4. In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand

5. ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies

6. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice

7. Circulating hematopoietic stem/progenitor cell subsets contribute to human hematopoietic homeostasis

8. A genetic association study of circulating coagulation factor VIII and von Willebrand factor levels

9. The effects of pathogenic and likely pathogenic variants for inherited hemostasis disorders in 140 214 UK Biobank participants

10. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

11. Distinct roles for PARP-1 and PARP-2 in c-Myc–driven B-cell lymphoma in mice

12. Inhibition of MYC translation through targeting of the newly identified PHB-eIF4F complex as a therapeutic strategy in CLL

13. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

14. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

16. Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL

17. Novel variants in GALE cause syndromic macrothrombocytopenia by disrupting glycosylation and thrombopoiesis

18. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma

19. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

20. Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

21. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

22. TNF-α–driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging

23. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis

25. A landscape of germ line mutations in a cohort of inherited bone marrow failure patients

26. Crebbp loss cooperates with Bcl2 overexpression to promote lymphoma in mice

27. Initiation of acute graft-versus-host disease by angiogenesis

30. Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors

31. Validating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

32. Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

33. Hematopoietic Cell Transplantation in First Remission in AML in Mexico: Very Low Rates Derived from Early Relapses and Lack of Access

34. Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

35. Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?

36. Clinical Impact of Sars-Cov-2 Vaccination in COVID-19 Outcomes in Patients Diagnosed with Hematologic Malignancies: Real-World Evidence of Two Years of Pandemic

37. Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

38. Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

39. Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

40. Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

41. Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial

42. Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction

43. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

44. IL-4 enhances expression and function of surface IgM in CLL cells

45. Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance

48. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

49. A human genome editing–based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features

50. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

Catalog

Books, media, physical & digital resources